OUR SPEAKERS
Joe Coffie, CCRA
Director of Clinical Operations at Imago Biosciences
Joe Coffie, CCRA
Director of Clinical Operations at Imago Biosciences
Joe Coffie has a proven track record of over twenty years of experience in building and leading highly functional Clinical Operations departments in small to medium-sized companies. His expertise lies in developing and implementing efficient operational strategies that improve clinical trial timelines and quality. Joe possesses exceptional skills in team building, cross-functional collaboration, and project management, which have helped him successfully lead clinical trials from phase I to IV.
Joe has a keen eye for identifying process inefficiencies and implementing innovative solutions to address them. His expertise in streamlining processes, optimizing resource allocation, and improving communication has enabled him to achieve significant cost savings in his organizations.
Joe's leadership and strategic vision have also helped smaller companies grow and achieve their business objectives. His ability to identify and leverage opportunities has enabled him to take smaller companies to the next level. Joe's deep knowledge of the clinical trial process, coupled with his business acumen, has made him a valuable asset for companies looking to expand their operations in the clinical research industry.
Joe has a keen eye for identifying process inefficiencies and implementing innovative solutions to address them. His expertise in streamlining processes, optimizing resource allocation, and improving communication has enabled him to achieve significant cost savings in his organizations.
Joe's leadership and strategic vision have also helped smaller companies grow and achieve their business objectives. His ability to identify and leverage opportunities has enabled him to take smaller companies to the next level. Joe's deep knowledge of the clinical trial process, coupled with his business acumen, has made him a valuable asset for companies looking to expand their operations in the clinical research industry.
Kiren Kanetkar
Vice President, Data & Analytics at Pendulum Therapeutics
Kiren Kanetkar
Vice President, Data & Analytics at Pendulum Therapeutics
Kiran Kanetkar is an accomplished Technology Executive Leader passionate about solving business problems that deliver business value. He has subject matter expertise in delivering business strategy that is powered by Data and Analytics (DNA). His hands-on approach ensures technical debt is retired using modern agile technology architecture that leverages modern cloud and microservices based IT landscape. Currently Kiran works as VP of Data and cs. He has completed Bachelor of Mechanical Engineering from VJTI, Mumbai, Post Graduate Diploma in Management from NITIE, Mumbai and an MBA from Ross School of Business at University of Michigan.
Amir Emadzadeh
Director at Genentech (Roche)
Amir Emadzadeh
Director at Genentech (Roche)
Amir Emadzadeh holds a PhD in Electrical Engineering from the University of California at Los Angeles (UCLA). Over his 14 years of work experience, he has been granted 10+ patents while at top Silicon Valley companies, including Qualcomm, Nvidia, and Google (Waymo). He is a Director of software in the Digital Transformation Office (DTO) at Genentech (Roche). He is also an adjunct Professor at California Science and Technology University (CSTU). Most recently, he was a Director of data science at Gilead sciences, where he led a team of data scientists and software developers dedicated to improving different aspects of clinical trials. Amir is very passionate about employing AI/ML techniques and automation to tackle pharma/healthcare industry challenges. Some of his recent work includes data-driven feasibility analysis for clinical trials (e.g., clinical trial site/investigator ranking, country assessment, diversity analysis & patient enrollment forecasting), extracting insights from clinical trial documents and sentiment analysis using NLP technology, and medical image segmentation/classification using deep neural networks.